Compare Novavax Inc (NVAX) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Teucrium Soybean Fund — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Teucrium Soybean Fund trades at $25.86. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SOYB | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $11.19 | $25.88 |
52-Week Low | $6.22 | $21.07 |
Enterprise Value | $800.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
SOYB trades at $25.88, up 1.53% today, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators but lacks available financial ratio data. Recent news highlights potential tailwinds from China's $17 billion U.S. crop purchase pledge through 2028, which may benefit agricultural sector stocks.
The stock's outlook is cautiously optimistic due to positive technical signals and favorable sector news, but investment is tempered by absent fundamental metrics and reliance on broader agricultural market trends. Key risks include commodity price volatility and execution uncertainties in trade agreements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
